Loading...
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
BACKGROUND: In the past few years, new drugs made their appearance in the first-line setting of treatment for metastatic renal cell carcinoma (mRCC), and cabozantinib is one among them. The present systematic review aims to point out any evidence published to date about first-line treatment with cab...
Na minha lista:
| Udgivet i: | Cancer Manag Res |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6159801/ https://ncbi.nlm.nih.gov/pubmed/30288108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S160485 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|